Search
Artemisia vulgaris root
go.drugbank.com/drugs/DB14170ApprovedArtemisia vulgaris root allergenic extract is used in allergenic testing.
Mixtures: WEED MIX Number 7BProducts: LAIS Beifuß 1000 UA SublingualtablettenTrimethoprim
go.drugbank.com/drugs/DB00440ApprovedInvestigationalVet approvedTrimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it … [L11893] Trimethoprim is often used in combination with [sulfamethoxazole] due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of
Mixtures: TRIMETOPRIMA 40 MG/5 ML SULFAMETOXAZOL 200MG/5 ML SUSPENSION, Bactrim 200 mg + 40 mg/5 mL SüspansiyonCategories: MATE 2 Inhibitors, MATE 2 SubstratesTuroctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalN-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain [F3685]. … Turoctocog alfa pegol is a pegylated version of [turoctocog alfa]. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019.
Products: ESPEROCT® 1500 UI, ESPEROCT® 2000 UIIpilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigational[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126] … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Categories: Immunoglobulin G, CTLA-4-directed Blocking AntibodyProducts: YERVOY 5 mg/ml concentrate for solution for infusion, YERVOY®5 MG /ML SOLUCION INYECTABLE PARA INFUSION INTRAVENOSARavulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalRavulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis.
Categories: Complement C5 inhibitorsProducts: Ultomiris 300 mg/3 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (1 adet), ULTOMIRIS ® RAVULIZUMAB 100MG/ML.Tetracaine
go.drugbank.com/drugs/DB09085ApprovedInvestigationalVet approvedTetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.
Mixtures: Pliaglis 70 mg/g + 70 mg/g Creme, Pliaglis 70 mg/g + 70 mg/g creamSynonyms: 2-(dimethylamino)ethyl 4-(butylamino)benzoate, 2-(Dimethylamino)ethyl p-(butylamino)benzoateDiiodohydroxyquinoline
go.drugbank.com/drugs/DB09115ApprovedDiiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. … Iodoquinol is not currently available in any FDA-approved products.
Mixtures: Hydrocortisone 2.5% / Iodoquinol 1% / Ketoconazole 2%, Iodoquinol 1% - Hydrocortisone Acetate 2% - Aloe Polysaccharides 1%Categories: Heterocyclic Compounds, 2-RingFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigationalFidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. … [A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: Tiacumicin BRisdiplam
go.drugbank.com/drugs/DB15305ApprovedInvestigationalRisdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). … [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).
Categories: MATE 2 Inhibitors, Survival of Motor Neuron 2 Splicing ModifierProducts: Evrysdi Powder for oral solution 0.75 mg/mL, EVRYSDI POWDER FOR ORAL SOLUTION 0.75 MG/ML